> Drug giant GlaxoSmithKline said it has offered to donate 50 million doses of a pandemic vaccine to the World Health Organization in the event of a global flu outbreak, according to a company spokesman. Report
> Merck KGaA's Merck Serono drugs unit has been approached by other companies and isn't for sale, Elmar Schnee, who heads the unit, told French daily La Tribune. Report
> Bayer and Onyx Pharmaceuticals said Japanese regulators gave the nod for Nexavar as a treatment for patients with inoperable liver cancer. Report
> The FDA has given tentative approval to Teva Pharmaceutical Industries for its generic version of a drug for eye infections. Report
> Johnson & Johnson said six-month study data showed its experimental stent was better than Boston Scientific's Taxus at preventing re-growth of tissue within the tiny devices, used to prop open heart arteries that have been cleared of plaque. Report
> Older men using Boehringer Ingelheim's Flomax to treat urinary problems are more than twice as likely to suffer serious complications after cataract surgery, a study has found. Report
> The UK's Vectura has blueprinted its late-stage plans for two key drug programs. Report
> Now that Genentech has been absorbed by Roche, Amgen holds the boasting rights to the title of world's leading biotech company. And it also faces the most direct threat from biosimilars, or follow-on biologics. Report
> A new report out from the Milken Institute ranks Boston, Philadelphia and San Francisco as the nation's most successful metropolitan areas when it comes to sustaining life sciences value. Report
> Switzerland's Santhera Pharmaceuticals took a turn at the stock market's whipping post this morning after announcing that its lead drug missed its primary endpoint in a late-stage study. Its shares swiftly plunged 30 percent on the news. Report
> Panelists at the BIO Convention's Ernst & Young's Global Biotechnology Report session, which examined what led the industry to the state it's in now and how to survive these tough times, say the "rifle-shot" approach to drug development may save money in the short-term, but will hurt companies. Report
> In other BIO-inspired announcements, Maryland Governor Martin O'Malley unveiled plans for the Maryland Biotechnology Center, a one-stop shop to help the state's biotech industry. Report
> FierceHealthcare takes a look at some of the top paid health plan CEOs. Report
And Finally... A new strain of MRSA seems to be triggering a deadly form of pneumonia in people who catch flu, experts say. Report